viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals get set for LSE debut as first medicinal cannabis company listed on main market

MGC Pharmaceuticals Ltd's (ASX:MXC) (FRA:H5O) (LON:MXC) Co-founder and MD Roby Zomer joins Proactive London to explain why the company has chosen to list on the London Stock Exchange (LSE) on Tuesday, February 9. 

This move will mean the firm will become the first medicinal cannabis company to be admitted to the main market. 

This follows a strongly supported £6.5 million share placement led by leading UK institutional fund managers and supported by UK family office and professional high net worth investors.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.07 AUD

Market: ASX
Market Cap: $156.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...


MGC Pharma's new head of global sales has big ambitions and says they're...

Proactive's Andrew Scott speaks with MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKT:MGCLF) recently appointed global chief sales officer Nicole Godresse. She'll lead the company’s global sales and marketing initiatives across Australia and New Zealand as well as build and implement a strong and...

on 1/2/21

2 min read